Archives of disease in childhood. Fetal and neonatal edition · 2026
Variations in antibiotic use in late preterm and term newborns from 2012 to 2020: a nationwide population-based observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gyllensvärd Johan, Studahl Marie, Gustavsson Lars, Hentz Elisabet, Åkesson Karin, Li Huiqi, Norman Mikael, Elfvin Anders
Аннотация
OBJECTIVE: To quantify regional and unit variations in antibiotic use during the first week of life, incidence of early-onset sepsis (EOS) and mortality in late-preterm and term newborns in Sweden.
DESIGN: A nationwide cohort study.
SETTING: The Swedish Neonatal Quality Register, a register of all newborns admitted for neonatal care in Sweden.
PATIENTS: All late-preterm and term newborns (≥34 weeks' gestation) admitted to a neonatal unit from 1 January 2012 to 31 December 2020.
MAIN OUTCOME MEASURES: The proportion of antibiotic use, incidence of EOS and mortality in late-preterm and term newborns.
RESULTS: Out of 1 025 515 newborns, 19 286 neonates (1.9%) received antibiotics with a 2-fold to 5-fold variation across regions (1.3%-3.0%) and units (0.9%-4.3%). Duration of antibiotic therapy (median) varied across regions from 7-10 days for infants with EOS, and 4-7 days for infants with no sepsis. Incidence of EOS ranged from 0.33 to 0.93 per 1000 live births between regions. The number of infants treated per EOS case varied 2-fold to 15-fold across regions (22-39) and units (7-113). All-cause mortality and EOS-associated mortality ranged across regions from 0.21 to 0.54 per 1000 live births and 0.0 to 34.9 (3 of 86 newborns) per 1000 infants with EOS.
CONCLUSIONS: This nationwide study revealed wide variations in antibiotic use and in the number of infants treated per EOS case. The results indicate a disproportionate antibiotic use in relation to the incidence of EOS. This emphasises the need for future efforts to minimise unwarranted antibiotic use.
DESIGN: A nationwide cohort study.
SETTING: The Swedish Neonatal Quality Register, a register of all newborns admitted for neonatal care in Sweden.
PATIENTS: All late-preterm and term newborns (≥34 weeks' gestation) admitted to a neonatal unit from 1 January 2012 to 31 December 2020.
MAIN OUTCOME MEASURES: The proportion of antibiotic use, incidence of EOS and mortality in late-preterm and term newborns.
RESULTS: Out of 1 025 515 newborns, 19 286 neonates (1.9%) received antibiotics with a 2-fold to 5-fold variation across regions (1.3%-3.0%) and units (0.9%-4.3%). Duration of antibiotic therapy (median) varied across regions from 7-10 days for infants with EOS, and 4-7 days for infants with no sepsis. Incidence of EOS ranged from 0.33 to 0.93 per 1000 live births between regions. The number of infants treated per EOS case varied 2-fold to 15-fold across regions (22-39) and units (7-113). All-cause mortality and EOS-associated mortality ranged across regions from 0.21 to 0.54 per 1000 live births and 0.0 to 34.9 (3 of 86 newborns) per 1000 infants with EOS.
CONCLUSIONS: This nationwide study revealed wide variations in antibiotic use and in the number of infants treated per EOS case. The results indicate a disproportionate antibiotic use in relation to the incidence of EOS. This emphasises the need for future efforts to minimise unwarranted antibiotic use.